Clinical trial
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
NCT00311740 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00311740 |
|---|---|
| Title | A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) |
| Official title | A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan, Hydrochlorothiazide |
| Enrollment | 582 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Apr 6, 2006 |
| Last update posted | Feb 23, 2017 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: